New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Core Insights - Exicure, Inc. announced that results from its Phase 2 study of burixafor will be presented at the 67th ASH Annual Meeting in December 2025 [1][2] - Burixafor is a small molecule CXCR4 antagonist aimed at mobilizing hematopoietic progenitor cells for transplantation in multiple myeloma patients [2][5] Study Details - The Phase 2 trial (NCT05561751) is an open-label, multicenter study assessing burixafor in patients undergoing autologous hematopoietic cell transplantation [2][4] - The combination of burixafor, G-CSF, and propranolol showed an excellent safety profile, with 18 out of 19 patients proceeding to transplantation [3][4] Presentation Information - The oral presentation will take place on December 8, 2025, at 5:45-6:00pm EST, focusing on the safety and efficacy of burixafor in mobilizing hematopoietic progenitor cells [4] Product Overview - Burixafor (GPC-100) is designed to enhance the mobilization of hematopoietic stem cells from the bone marrow into peripheral blood for autologous stem cell transplant procedures [5] - The drug is also being explored for use in other conditions such as sickle cell disease and acute myeloid leukemia [5][6] Company Background - Exicure, Inc. is a clinical-stage biotechnology company focused on developing therapies for hematologic diseases, with burixafor as its lead program [6]